Acute psychotic disorder.
Conditions
Interventions
Intervention 1: Tab olanzapine, 15 mg daily, until onset of drug response according to Positive and Negative Symptom Scale. Intervention 2: Tab risperidone, 4.5 mg daily, until onset of drug response
Treatment - Drugs
Tab olanzapine, 15 mg daily, until onset of drug response according to Positive and Negative Symptom Scale
Tab risperidone, 4.5 mg daily, until onset of drug response according to Positive and Negative Symptom Scale
Tab haloperidol, 6 mg daily, until onset of drug response according to Positive and Negative Symptom Scale
Cap thiothixene, 15 mg daily, until onset of drug response according to Positive and Negative Symptom Scale
Sponsors
Isfahan University of Medical Sciences, Behavioral Sciences Research Center
Eligibility
Sex/Gender
All
Age
15 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1) 15-60 years aged; 2) onset of psychotic symptoms (delusion, hallucination, thought disorder or bizarre behavior) through 30 days before the study; 3) current diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, substance induced psychotic disorder, psychotic disorder due to GMC and psychotic disorder NOS according to DSM-IV-TR criteria; 4) a score of at least four on at least two of the positive subscales or at least five on at least one of the positive subscales of the Positive and Negative Symptoms Scale 5) written informed consent. Exclusion criteria: 1) any serious medical condition that may interfere with safe study participation; 2) receiving any antipsychotic treatment for more than seven days during 30 days before; 3) receiving any long acting antipsychotic through three months before the study; 4) incidence of acute psychosis in context of mood disorders; 5) pregnancy or nursing in women; 6) history of sever drug reaction to the drugs in study; 7) simultaneous use of anticonvulsants, antidepressants or mood stabilizer drugs
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Onset of antipsychotic response. Timepoint: Eache 2 days. Method of measurement: Positive subscales of Positive and Negative Symptoms Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sedation. Timepoint: Each 2 days. Method of measurement: Check list.;Extra pyramidal side effects. Timepoint: Each 2 days. Method of measurement: Check list.;Weight gain. Timepoint: Each 2 days. Method of measurement: Check list. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamze Rostami
Isfahan University of Medical Sciences, Department of Psychiatry
Outcome results
None listed